AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biopharm company to gain commercial rights to anthrax vaccine candidate.
2003 NOV 12 - (NewsRx.com & NewsRx.net) -- VaxGen, Inc., (VXGN) has entered into a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that gives VaxGen exclusive, worldwide rights to develop and commercialize a recombinant anthrax vaccine candidate based on technology developed by USAMRIID.
The agreement is subject to certain rights retained by the government.
The license agreement obligates VaxGen to pay USAMRIID an execution fee, patent maintenance fees, anniversary fees, milestones and royalties. It gives VaxGen exclusive license to U.S. patent 6,387,665 (Method of Making a Vaccine for Anthrax) and an exclusive field of use license to U.S. patent 6,316,006 (Asporagenic B. anthracis Expression System) for the purpose of developing and commercializing a vaccine against anthrax.
VaxGen had been using the technology since early 2002 under a Cooperative Research and Development Agreement and a letter of intent regarding patent rights with USAMRIID. It is the same technology VaxGen is using to develop its recombinant Protective Antigen anthrax vaccine, rPA102, under contract from the National Institute of Allergy and Infectious Diseases (NIAID).
VaxGen announced on September 30, 2003, that it had been awarded an $80.3 million NIAID contract to fund many of the ...
- FDA Clears VaxGen's IND for Anthrax Vaccine Candidate; Clinical Development to...
- Press release article from: PR Newswire May 27, 2003 700+ words
...the existing licensed anthrax vaccine. The vaccine candidate's efficacy will be...development of an rPA anthrax vaccine candidate. Deliverables under...contract. VaxGen's anthrax vaccine candidate is based on the pioneering...
- VaxGen Awarded $80.3 Million NIAID Contract for Advanced Development of Anthrax...
- Press release article from: PR Newswire October 1, 2003 700+ words
...development of its anthrax vaccine candidate, rPA102. The...contract. VaxGen's anthrax vaccine candidate is based on the...anthrax toxins. The vaccine candidate cannot cause anthrax...the need for an anthrax vaccine that has an improved...
- Phase I clinical trial results of anthrax vaccine candidate reported.
- News wire article from: Bioterrorism Week March 29, 2004 700+ words
...AVA), the anthrax vaccine currently...Antigen (PA) Anthrax Vaccine (rPA102...administration of the vaccine candidate at each dose...models. The vaccine candidate cannot cause...need for an anthrax vaccine with an improved...
- VaxGen Reports Phase I Clinical Trial Results of Anthrax Vaccine Candidate.
- Press release article from: PR Newswire March 2, 2004 700+ words
...AVA), the anthrax vaccine currently...Antigen (PA) Anthrax Vaccine (rPA102...administration of the vaccine candidate at each dose...models. The vaccine candidate cannot cause...need for an anthrax vaccine with an improved...
- VaxGen awarded $80.3 M NIAID contract for advanced development of anthrax...
- News wire article from: Asia Africa Intelligence Wire September 30, 2003 700+ words
...Diseases (NIAID) for the advanced development of its anthrax vaccine candidate, rPA102. The 3-year contract is intended to...significantly larger contract for a national stockpile of anthrax vaccine. The new NIAID contract is intended to fund animal...
- Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax...
- Press release article from: Business Wire May 5, 2008 700+ words
...source for an advanced anthrax vaccine candidate to meet planned procurement...rPA 102, a recombinant anthrax vaccine candidate, which is composed of...select an advanced rPA anthrax vaccine candidate from a domestic manufacturer...
- VaxGen Finalizes Commercial Rights To Anthrax Vaccine Candidate.
- Press release article from: PR Newswire October 13, 2003 700+ words
...commercialize a recombinant anthrax vaccine candidate based on technology developed...of rPA102. VaxGen's anthrax vaccine candidate is based on the pioneering...efficacy of the Company's anthrax vaccine candidate, rPA102, or the Company...
- VaxGen Publishes Results of Phase I Clinical Trial of Anthrax Vaccine Candidate.
- Press release article from: PR Newswire August 14, 2006 700+ words
...of its candidate anthrax vaccine rPA102 were published...Antigen (rPA102) Anthrax Vaccine: A Randomized...injections of the vaccine candidate yielded higher antibody...the investigational anthrax vaccine produced an immune...
- VaxGen Begins Phase II Trial of Anthrax Vaccine Candidate.
- Press release article from: PR Newswire April 15, 2004 700+ words
...need for a next-generation anthrax vaccine, VaxGen is particularly pleased...optimal dosing schedule for the anthrax vaccine candidate, both for prevention and treatment...to address the need for an anthrax vaccine that has an improved safety...
- Anthrax vaccine candidate receives fast track designation.
- Newspaper article from: Biotech Business Week February 16, 2004 700+ words
...granted a Fast Track designation to the company's anthrax vaccine candidate, rPA102. The Fast Track designation means that...review status to the license application for our anthrax vaccine candidate," said Carmen Betancourt, VaxGen's senior...
Source: HighBeam Research, Biopharm company to gain commercial rights to anthrax vaccine...